JCTC vs FENC vs UFPI vs LCTX vs TREX

For growth investors, Fennec Pharmaceuticals Inc.

(FENC) is the stronger pick with 123. 7% revenue growth year-over-year, versus -12. 4% for Jewett-Cameron Trading Company Ltd. (JCTC). UFP Industries, Inc. (UFPI) offers the better valuation at 16. 9x trailing P/E (18. 0x forward), making it the more compelling value choice. Analysts rate Fennec Pharmaceuticals Inc. (FENC) a "Buy" — based on 7 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, UFP Industries, Inc.

(UFPI) is the cheapest at 16. 9x versus Trex Company, Inc. at 22. 6x. On forward P/E, UFP Industries, Inc. is actually cheaper at 18. 0x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: UFP Industries, Inc. wins at 3. 95x versus Trex Company, Inc. 's 7. 25x.

Over the past 5 years, Fennec Pharmaceuticals Inc.

(FENC) delivered a total return of +15. 9%, compared to -62. 7% for Trex Company, Inc. (TREX). Over 10 years, the gap is even starker: TREX returned +248. 9% versus JCTC's -55. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Jewett-Cameron Trading Company Ltd.

(JCTC) is the lower-risk stock at 0. 71β versus Fennec Pharmaceuticals Inc. 's 1. 78β — meaning FENC is approximately 149% more volatile than JCTC relative to the S&P 500. On balance sheet safety, Lineage Cell Therapeutics, Inc. (LCTX) carries a lower debt/equity ratio of 6% versus 22% for Trex Company, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Fennec Pharmaceuticals Inc.

(FENC) is pulling ahead at 123. 7% versus -12. 4% for Jewett-Cameron Trading Company Ltd. (JCTC). On earnings-per-share growth, the picture is similar: Fennec Pharmaceuticals Inc. grew EPS 97. 3% year-over-year, compared to -657. 1% for Jewett-Cameron Trading Company Ltd.. Over a 3-year CAGR, TREX leads at 2. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Trex Company, Inc.

(TREX) is the more profitable company, earning 16. 2% net margin versus -436. 5% for Lineage Cell Therapeutics, Inc. — meaning it keeps 16. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TREX leads at 22. 0% versus -251. 6% for LCTX. At the gross margin level — before operating expenses — LCTX leads at 99. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, UFP Industries, Inc. (UFPI) is the more undervalued stock at a PEG of 3. 95x versus Trex Company, Inc. 's 7. 25x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, UFP Industries, Inc. (UFPI) trades at 18. 0x forward P/E versus 54. 3x for Fennec Pharmaceuticals Inc. — 36. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for FENC: 159. 7% to $18. 00.

In this comparison, UFPI (1.

7% yield) pays a dividend. JCTC, FENC, LCTX, TREX do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, UFP Industries, Inc.

(UFPI) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 94), 1. 7% yield, +232. 5% 10Y return). Fennec Pharmaceuticals Inc. (FENC) carries a higher beta of 1. 78 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (UFPI: +232. 5%, FENC: -42. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (JCTC (Basic Materials) and FENC (Healthcare) and UFPI (Basic Materials) and LCTX (Healthcare) and TREX (Industrials)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: JCTC is a small-cap quality compounder stock; FENC is a small-cap high-growth stock; UFPI is a small-cap deep-value stock; LCTX is a small-cap high-growth stock; TREX is a small-cap quality compounder stock. UFPI pays a dividend while JCTC, FENC, LCTX, TREX do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.